Pharmaceutical giant Eli Lilly is stepping up its battle against obesity with a $3.5 billion investment in a new manufacturing facility in Pennsylvania's Lehigh Valley, marking another major expansion of its US production network.

 

The company broke ground on the facility on Thursday, which will manufacture next-generation injectable medicines, including retatrutide, an experimental triple-hormone drug being developed as a potential treatment for obesity, type 2 diabetes and other metabolic conditions.

 

The project is part of Lilly's ambitious $50 billion push to expand medicine manufacturing in the United States. It is also the latest addition to the 10 manufacturing sites the company has announced across the country since 2020.

 

The new facility will create approximately 850 high-wage jobs, including positions for engineers, scientists, laboratory technicians and operations personnel. Another 2,000 construction jobs are expected during the building and commissioning phases.

 

Lilly Chairman and CEO David A. Ricks said the investment would strengthen the company's ability to meet growing demand for advanced obesity treatments.

 

"Obesity is one of the biggest health challenges of our time, and the science to treat it is moving quickly. Retatrutide is one of several next-generation medicines we're developing that could help millions more people living with obesity, type 2 diabetes, or both. This $3.5 billion investment means we'll be able to make these medicines in Pennsylvania for people here at home and around the world."

 

A major focus of the new facility will be retatrutide, Lilly's investigational once-weekly treatment that targets three hormone receptors — GIP, GLP-1 and glucagon.

 

The experimental drug represents the next generation of obesity treatments, building on the growing scientific interest in hormone-based therapies for weight management and metabolic disease.

 

Lilly is currently evaluating retatrutide in multiple Phase 3 clinical trials involving people with obesity or overweight, type 2 diabetes, knee osteoarthritis pain, obstructive sleep apnea, chronic lower back pain, cardiovascular risks and metabolic dysfunction-associated steatotic liver disease.

 

However, the drug remains investigational and has not been approved for human use or commercial sale.

 

Beyond expanding production capacity, Lilly plans to equip the Lehigh Valley facility with advanced manufacturing technologies, including artificial intelligence, machine learning, digitally integrated systems and advanced data analytics.

 

The company says automation will be embedded throughout the site to improve operational efficiency, strengthen quality control and ensure consistent production of medicines.

 

Edgardo Hernandez, Executive Vice President and President of Lilly Manufacturing Operations, highlighted the stringent quality checks involved in producing its medicines.

 

"Before a dose of medicine leaves one of our sites, each production run goes through more than 5,000 documented steps and each unit is imaged and inspected more than 70 times to check for defects. These are just a few examples of the quality control we take to protect our patients. Lehigh Valley will build on that discipline with next-generation automation and digital systems, so we can do things right the first time and help patients count on their medicines for years to come, made in Pennsylvania."

 

The project is also being positioned as a major economic boost for Pennsylvania, strengthening the state's growing life sciences and advanced manufacturing sectors.

 

Pennsylvania Governor Josh Shapiro described the investment as a milestone for the Commonwealth's innovation economy and workforce.

 

"Today marks another historic milestone in Pennsylvania's thriving life sciences sector and reinforces my Administration's commitment to advancing innovation, strengthening the economy, and creating good-paying jobs across the Commonwealth. We secured this historic, life-changing investment thanks to Pennsylvania's world-class workforce, research institutions, infrastructure, and resources, and my Administration will continue working hard to ensure Pennsylvania remains a place where groundbreaking discoveries can translate into meaningful economic opportunities and results for patients and families."

 

Lilly is also committing up to $1 million over five years through the Upper Macungie Township Community Fund to support a new quality-of-life initiative for families in the Lehigh Valley.

 

The proposed programme will focus on nutrition, healthy living, access to fresh food, health resources and community activities.

 

Jeff Fleischaker, Chairman of the Upper Macungie Township Board of Supervisors, welcomed the company's arrival.

 

"We are thrilled to be able to celebrate the groundbreaking of the new Lilly facility in Upper Macungie Township. The Board of Supervisors, staff and residents of Upper Macungie are excited to welcome Lilly to our community. We are all looking forward to seeing what we can do, together, to make every day better in Upper Macungie."

 

US Senator Dave McCormick also welcomed the investment, highlighting its potential to boost employment and strengthen domestic pharmaceutical manufacturing.

 

"Lilly's $3.5 billion investment in the Lehigh Valley is another major win for Pennsylvania, bringing 850 high-paying jobs, strengthening American manufacturing, and cementing the Commonwealth's position as a leader in life sciences and innovation. When I talk about building a pro-growth environment in Pennsylvania, this is the type of investment I am working to attract."